ADI‑PEG 20 plus Gemcitabine and nab-Paclitaxel Shows Robust Anti-tumor Activity in Advanced Pancreatic Cancer

CHICAGO, June 6, 2016 /PRNewswire/ — Polaris Group announced today that the phase III study of second line ADI‑PEG 20 plus best supportive care versus placebo plus best supportive care in patients with advanced hepatocellular carcinoma (HCC) did not meet its primary endpoint of demonstrating overall survival (OS) benefits. Median OS was 7.8 months for ADI‑PEG 20 vs. 7.4 months for placebo (p = 0.884, HR=1.022 [95% CI: 0.847, 1.233]).

Polaris Group Announces Issuance of New Patent Protecting Lead Product Candidate ADI‑PEG 20

SAN DIEGO, May 16, 2016 — Polaris Group announced today that it has received notification that the United States Patent and Trademark Office will issue to Polaris Group a new utility patent that will contain claims protecting the pharmaceutical composition of ADI‑PEG 20 which Polaris Group plans to commercialize upon receiving regulatory approval, as well as claims covering therapeutic use of the compositions of ADI‑PEG 20 for the treatment of a variety of cancer indications.

Polaris Group’s ADI‑PEG 20 Shows Robust Clinical Activity in Malignant Plural Mesothelioma When Combined with Standard First-Line Chemotherapy Regimen

SAN DIEGO, May 5, 2016 – Polaris Group announced results from an ongoing phase 1 study that combines its lead therapeutic ADI‑PEG 20 (pegylated arginine deiminase) with the standard first-line chemotherapy (cisplatin + pemetrexed doublet) in malignant pleural mesothelioma (MPM) demonstrating promising response rates.

Polaris Group Shares Listed on the Emerging Stock Board of the Taipei Exchange

Taipei, February 15, 2016 – Polaris Group announced today that its shares have been listed for trading on the Emerging Stock Board (ESB) of the Taipei Exchange (TPEx).

Polaris Group Completes Construction of Its GMP Manufacturing Facility in China

SAN DIEGO, January 22, 2016 – Polaris Group announced today that its wholly owned subsidiary DesigneRx Pharmeceuticals (DRX) (Chengdu) has completed the building constructions of its GMP manufacturing facility for biological drugs in Chengdu, China.

Polaris Group Subsidiary Announces Expansion of cGMP Manufacturing Facility

VACAVILLE, CALIFORNIA, January 5, 2016 – Polaris Group today announced that its subsidiary DesigneRx Pharmaceuticals, Inc. (DRX) has completed construction of its new, expanded cGMP facility for manufacturing biological pharmaceuticals in Vacaville, California.

Polaris Group Acquires 100% Ownership of TDW Group

Taipei, October 12, 2015 – Polaris Group announced today that it has acquired ownership of all outstanding shares of TDW Group in a share exchange transaction. Prior to the acquisition, Polaris Group owned a 27% stake in TDW Group and following the acquisition, TDW Group became a wholly-owned subsidiary of Polaris Group.

Polaris Group’s Lead Therapeutic ADI‑PEG 20 Shows Activity against Primary Acute Myeloid Leukemia

SAN DIEGO, June 25, 2015 – Polaris Group announced today that its lead therapeutic ADI‑PEG 20 (pegylated arginine deiminase) was shown to have activity against primary acute myeloid leukemia (AML), both in vitro and in vivo, as reported in a research article published in the journal Blood.

Additional Tumor Type Cohorts Added to the Ongoing Phase 1 Study Combining ADI‑PEG 20 with Cisplatin and Pemetrexed Based on New Research Results

SAN DIEGO, May 22, 2015 – Polaris Group announced today that it has filed a protocol amendment with the FDA to include two additional dose expansion cohorts treating uveal melanoma and glioblastoma in its ongoing phase 1 study that tests its lead therapeutic ADI‑PEG 20 (pegylated arginine deiminase) in combination treatment with the standard first-line chemotherapy (cisplatin + pemetrexed doublet) in malignant plural mesothelioma (MPM) and non-squamous non-small cell lung carcinoma (NSCLC).

Polaris Group’s ADI‑PEG 20 Restores Cisplatin Sensitivity to Cisplatin-Resistant Non-Small Cell Lung Carcinoma Cells

SAN DIEGO, April 22, 2015 – Polaris Group announced today that its lead therapeutic ADI‑PEG 20 (pegylated arginine deiminase) restored cisplatin sensitivity to multiple cisplatin-resistant (CR) non-small cell lung carcinoma (NSCLC) cell lines in vitro.